Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 5
Submit an article Journal homepage
296
Views
18
CrossRef citations to date
0
Altmetric
Letter

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response

Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, ItalyCorrespondence[email protected]
,
Giuseppina LoglisciDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Laura CannellaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Paola FinsingerDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Marco ManciniDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Alessandra SerraoDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Michelina SantopietroDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
,
Adriano SalaroliDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
&
Giuliana AlimenaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
 show all
Pages 985-986 | Received 28 Oct 2011, Accepted 18 Nov 2011, Published online: 11 Jan 2012

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Janusz Krawczyk, Niamh Keane, Ciara Louise Freeman, Ronan Swords, Michael O'Dwyer & Francis J Giles. (2013) 5-Azacytidine for the treatment of myelodysplastic syndromes. Expert Opinion on Pharmacotherapy 14:9, pages 1255-1268.
Read now

Articles from other publishers (17)

Anthi Bouchla, Thomas P Thomopoulos, Sotirios G Papageorgiou, Christina Apostolopoulou, Constantinos Loucari, Efthimia Mpazani & Vasiliki Pappa. (2021) Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine. Epigenomics 13:14, pages 1129-1143.
Crossref
Jan Philipp Bewersdorf & Amer M. Zeidan. 2020. Diagnosis and Management of Myelodysplastic Syndromes. Diagnosis and Management of Myelodysplastic Syndromes 109 127 .
Eun-Ji Choi, Je-Hwan Lee, Han-Seung Park, Jung-Hee Lee, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo & Kyoo-Hyung Lee. (2019) Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 19:5, pages 290-299.e3.
Crossref
Rory M. Shallis & Amer M. Zeidan. (2018) More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology 18:1.
Crossref
Roman M. Shapiro & Alejandro Lazo-Langner. (2018) Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. BMC Hematology 18:1.
Crossref
Lesley J. Scott. (2016) Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia. Drugs 76:8, pages 889-900.
Crossref
A M Zeidan, M A Sekeres, G Garcia-Manero, D P Steensma, K Zell, J Barnard, N A Ali, C Zimmerman, G Roboz, A DeZern, A Nazha, E Jabbour, H Kantarjian, S D Gore, J P Maciejewski, A List & R Komrokji. (2015) Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia 30:3, pages 649-657.
Crossref
Eun-Ju Lee, Nikolai Podoltsev, Steven D. Gore & Amer M. Zeidan. (2016) The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. Blood Reviews 30:1, pages 1-10.
Crossref
Marianne B. Treppendahl, Lasse Sommer Kristensen & Kirsten Grønbæk. 2016. Epigenetic Biomarkers and Diagnostics. Epigenetic Biomarkers and Diagnostics 91 118 .
Daniel A. Pollyea & Jonathan A. Gutman. (2014) Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks. Current Hematologic Malignancy Reports 9:4, pages 421-431.
Crossref
Rafael BejarAllegra LordKristen Stevenson, Michal Bar-NatanAlbert Pérez-LadagaJacques ZaneveldHui WangBennett CaugheyPetar Stojanov, Gad Getz, Guillermo Garcia-Manero, Hagop Kantarjian, Rui ChenRichard M. StoneDonna Neuberg, David P. SteensmaBenjamin L. Ebert. (2014) TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 124:17, pages 2705-2712.
Crossref
Amer M. Zeidan, Ju-Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, Elisabeth Paietta, Janice Gabrilove, Harry P. Erba, Martin S. Tallman & Steven D. Gore. (2014) Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. British Journal of Haematology 166:3, pages 352-359.
Crossref
Marianne B. Treppendahl, Lasse S. Kristensen & Kirsten Grønbæk. (2014) Predicting response to epigenetic therapy. Journal of Clinical Investigation 124:1, pages 47-55.
Crossref
Amer M. Zeidan, Yuliya Linhares & Steven D. Gore. (2013) Current therapy of myelodysplastic syndromes. Blood Reviews 27:5, pages 243-259.
Crossref
Ellen J.B. Derissen, Jos H. Beijnen & Jan H.M. Schellens. (2013) Concise Drug Review: Azacitidine and Decitabine. The Oncologist 18:5, pages 619-624.
Crossref
H. Joachim Deeg, David T. Bowen, Steven D. Gore, Torsten Haferlach, Michelle M. Le Beau & Charlotte NiemeyerAmer M. Zeidan & Steven D. Gore. 2013. Myelodysplastic Syndromes. Myelodysplastic Syndromes 189 210 .
Raphael Itzykson, Sylvain Thépot, Bruno Quesnel, Francois Dreyfus, Christian Recher, Eric Wattel, Claude Gardin, Lionel Adès & Pierre Fenaux. (2012) Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. Blood 119:25, pages 6172-6173.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.